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A b s t r a c t
The ‘amyloid cascade hypothesis’ (ACH) is the most influential model of the pathogenesis of Alzheimer’s disease (AD). 
The hypothesis proposes that the deposition of β-amyloid (Aβ) is the initial pathological event in AD, leading to the 
formation of extracellular senile plaques (SP), tau-immunoreactive neurofibrillary tangles (NFT), neuronal loss, and 
ultimately, clinical dementia. Ever since the formulation of the ACH, however, there have been questions regarding 
whether it completely describes AD pathogenesis. This review critically examines various aspects of the ACH includ-
ing its origin and development, the role of amyloid precursor protein (APP), whether SP and NFT are related to the 
development of clinical dementia, whether Aβ and tau are ‘reactive’ proteins, and whether there is a pathogenic 
relationship between SP and NFT. The results of transgenic experiments and treatments for AD designed on the basis 
of the ACH are also reviewed. It was concluded: (1) Aβ and tau could be the products rather than the cause of neuro-
degeneration in AD, (2) it is doubtful whether there is a direct causal link between Aβ and tau, and (3) SP and NFT may 
not be directly related to the development of dementia, (4) transgenic models involving APP alone do not completely 
replicate AD pathology, and (5) treatments based on the ACH have been unsuccessful. Hence, a modification of the 
ACH is proposed which may provide a more complete explanation of the pathogenesis of AD.
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Introduction
The ‘amyloid cascade hypothesis’ (ACH) [57] is 
the most influential model of the pathology of Alzhei-
mer’s disease (AD) proposed over the last 25 years. 
As a  result, numerous studies of AD pathogenesis 
have been carried out [6,8] and potential treatments 
proposed and tested based on the ACH [69,113].
It was the discovery of β-amyloid (Aβ), the most 
important molecular constituent of senile plaques 
(SP) [49], and mutations of the amyloid precursor 
protein (APP) gene linked to early-onset familial 
AD (FAD) [27,50], which led to the original formula-
tion of the hypothesis [57]. The ACH proposed first, 
a  direct relationship between the development of 
Aβ, in the form of senile plaques (SP), and neuro-
fibrillary tangles (NFT) and second, between these 
lesions and clinical dementia. Hence, deposition of 
Aβ is the initial pathological event in AD, leading to 
the formation of SP, tau-immunoreactive NFT, neuro-
nal loss, and ultimately clinical dementia. The ACH 
is often regarded as the ‘conclusive model’ of the 
aetiology of early-onset FAD, and sporadic AD (SAD), 
a more complex disorder caused by a variety of fac-
tors, but resulting from essentially the same patho-
logical cascade [42,127]. 
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Aβ – β-amyloid, Apo E – apolipoprotein E, APP – amyloid precursor protein, PSEN1/2 – presenilin genes 1 and 2, NFT – neurofibrillary tangles 
Fig. 1. The amyloid cascade hypothesis (ACH) in its original form.
Since its publication there have been observa-
tions difficult to reconcile with the ACH and con-
cerns whether it completely describes AD pathogen-
esis [11,90]. First, transgenic mice, in which genes 
overexpress amyloid precursor protein (APP), do not 
reproduce the predicted cascade [39,90]. Second, SP 
and NFT are separated in brain both spatially [11] 
and temporally [39,82] questioning the pathogenic 
link between them. Third, Aβ and tau could be the 
reactive products of neurodegeneration rather than 
their cause, arising as a  consequence of oxidative 
stress [126]. Fourth, study of various neuronal injury 
biomarkers does not support a central pathological 
role for Aβ, especially in late-onset SAD [28]. These 
observations suggest a  more complex relationship 
between Aβ, tau, and AD pathogenesis than sug-
gested by the ACH. In addition, concentration on the 
ACH may have been to the detriment to the study 
of other possible aetiologies including: (1) pertur-
bation of vesicular trafficking, (2) disruption of the 
cytoskeletal network, and (3) disturbance of mem-
brane cholesterol [37]. These views are supported by 
a  critique of the ACH by Teplow [133] who argues 
that ‘insufficient rigour’ has been applied to studies 
of Aβ in AD based on the ACH and ‘confusion not 
clarity’ has been the result. 
This review critically examines various aspects 
of the ACH including its origin and development, 
the role of amyloid precursor protein (APP), wheth-
er SP and NFT are related to the development of 
clinical dementia, whether Aβ and tau are ‘reactive’ 
peptides, and whether there is a  pathogenic rela-
tionship between SP and NFT. The results of trans-
genic experiments and treatments for AD designed 
on the basis of the ACH are also reviewed. Finally, 
a modified scheme based on the ACH is proposed 
which may provide a more complete description of 
the pathogenesis of all forms of AD. 
Key observations in the development  
of the amyloid cascade hypothesis
The original formulation of the ACH as proposed 
by Hardy and Higgins [57] is shown in Figure 1. A num-
ber of key observations resulted in the formulation 
and subsequent development of the hypothesis:
1. Aβ was discovered as the most important mo-
lecular constituent of SP [49], emphasising the impor-
tance of amyloid peptides in AD. 
2. Altered proteolytic processing of APP and its 
accumulation were shown to be early events in AD 
and were followed by microglial activation, astrocy-
tosis, and dystrophic neurites (DN) [105]. 
3. Mutations of APP gene [27,50] were linked to 
early-onset FAD, the presence of point mutations in 
APP evidence that amyloid deposition was the caus-
ative factor [56]. Three main groups of APP mutations 
have been identified, i.e., those which act at: (a) the 
beta APP cleaving enzyme 1 (βACE1) site, (b) the gam-
ma APP cleaving enzyme site, and (c) the mid-domain 
of the Aβ region.
4. Formation of Aβ peptides was directly linked 
to APP processing with two events being necessary 
to generate Aβ [116]: (a) cleavage by βACE1 which 
cleaves APP on the amino side of Aβ resulting in 
a  large secreted derivative and an Aβ membrane- 
associated C-terminal derivative (CTFβ) and (b) cleav- 
age by g-secretase which cleaves CTFβ to release 
the Aβ peptide [63]. A  variety of Aβ peptides can 
be formed as a  result of cleavage of APP [54], the 
most common being Aβ42 [131], found largely in dis-
crete Aβ deposits [139], and the more soluble Aβ40, 
also found in association with blood vessels [86], 
and which may develop later in the disease [35]. In 
addition, Aβ43 may be formed and has a particular-
ly potent amyloidogenicity [115]. Mutations of APP 
within the Aβ coding region can also result in the 
deposition of Aβ38 in vessel walls, especially in those 
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cases with extensive cerebral amyloid angiopathy 
(CAA) [88]. Early toxic soluble oligomers could also 
be involved, which vary with a type of mutant, thus 
providing a genetic basis for variations in pathogen-
esis observed among FAD cases [46,48]. 
5. Subsequently, the most common form of ear-
ly-onset FAD was linked to mutations of presenilin 
(PSEN) genes PSEN1 [123] and PSEN2 [78]. Full length 
PSEN protein is composed of nine trans-membrane 
domains located on the endoplasmic reticulum mem-
brane. Endoproteolytic cleavage of PSEN and assem-
bly into g-secretase complex is followed by transport 
to the cell surface, thus potentially influencing APP 
processing [61]. Hence, mutant PSEN1 could enhance 
42-specific-g-secretase cleavage of normal APP re-
sulting in increased deposition of amyloid-forming 
species [129]. Alternatively, deficiency of PSEN1 may 
inhibit the normal cleavage of APP [34,141]. PSEN1 
also appears to alter the ratio of Aβ species, the ratio 
of Aβ40/42 being lower and the ratio of Aβ42/40 higher 
in PSEN1 cases compared with SAD [60]. 
6. Studies of FAD cases caused by APP717 (va line–
isoleucine) mutation showed them to have signifi-
cant numbers of tau-immunoreactive NFT support-
ing a  link between APP and degeneration of the 
cytoskeleton [75]. 
7. Early experiments using transgenic mice ex-
pressing high levels of APP resulted in Aβ deposition, 
synaptic loss, and gliosis [44]. 
8. In Down’s syndrome (DS), which replicates many 
of the features of AD pathology [5,9], water soluble 
peptides ending in residue 42 precede the formation 
of SP and also increase with age [114]. 
9. Aβ peptides are toxic and can induce cell death 
depending on cell type [55], Aβ toxicity being medi-
ated by the necrotic rather than the apoptotic path-
way [20,76]. 
10. Aβ may induce the phosphorylation of tau by: 
(a) directly interacting with a domain of APP (714-
723) [47,125], (b) by inducing tau protein kinase I 
and subsequently, tau proteins recognised by the 
antibody Alz-50 [132], (c) as a result of synergisms 
between Aβ and tau [100,101], or (d) by directly alter-
ing the phosphorylated state of tau [23]. 
11. Senile plaques and NFT acquire several ‘sec-
ondary’ constituents (Table I) which may be involved 
in the ma turation of Aβ deposits into SP [7] includ-
ing silicon and aluminium [82], acute-phase proteins 
such as a-antichymotrypsin and a2-macroglobulin 
[40,81,136] and their mediator interleukin-6 (IL-6) 
[122], intercellular adhesion molecules such as cell 
adhesion molecule 1 (CAM1) [40], apolipoprotein E 
(Apo E) which is present in the earliest stages of 
SP formation [145], apolipoprotein D (Apo D) [36], 
the heterodimeric glycoprotein clusterin, vibronec-
tin, the complement proteins C1q, C4, and C3 [137], 
blood proteins such as amyloid-P (especially in clas-
sic ‘cored’ SP) [67,68], cathepsins B/D [124], and the 
Table I. Molecular composition of senile plaques (SP) and neurofibrillary tangles (NFT) in Alzheimer’s disease 
(AD) (From: Armstrong [7])
Pathology Molecular composition
Diffuse SP APP (lacking C terminus), Aβ oligomers, especially Aβ42/43, apolipoprotein E, a1-antichy-
motrypsin, HSPG, complement proteins (C1q, C3, C4), amyloid-P, may contain neuronal 
and astrocytic markers
Primitive SP APP (N & C-terminal), Aβ42/43, free ubiquitin, conjugated ubiquitin, PHF-antigen, phos-
phorylated tau, chromogranin-A, bFGF, apolipoprotein E, interleukin-6, acetylcholines-
terase, cholinergic, somatostatin, GABA, neuropeptide-Y, parvalbumin, and catechol-
amine immunoreactive neurites 
Classic SP Aβ42/43 (‘core’), a-synuclein (‘ring’), Aβ40, actin, tubulin, phosphorylated tau, NF-pro-
tein, CAM, chromogranin-A (‘ring’), a2-macroglobulin, complement proteins (‘core’), 
immunoglobulins (‘core’), amyloid-P, a1-antichymotrypsin, antitrypsin, antithrombin III, 
apolipoprotein E and D (‘core’), DOPPEL, bFGF, PrP, may contain acetylcholinesterase, 
cholinergic, somatostatin, GABA, neuropeptide-Y, parvalbumin, and catecholamine + 
neurites (‘ring’), silicon/aluminium (‘core’), interleukin-6 (‘ring’)
Intracellular NFT Phosphorylated 3R/4R tau (C & N terminal), ubiquitin (C & N termini), MAP, NF-protein, 
apolipoprotein E, synaptophysin, bFGF, HSPG
Extracellular NFT Degraded tau (lacking N/C termini), GFAP, Aβ, ubiquitin (lacking N-terminus), amyloid-P, 
Apo E
Aβ – β-amyloid, APP – amyloid precursor protein, bFGF – basic fibroblast growth factor, CAM – cell adhesion molecule, GFAP – glial fibrillary acidic protein, HSPG 
– heparan sulfate proteoglycan, MAP – microtubule associated proteins, NF-protein – neurofilament protein, PHF – paired helical filament, PrP – prion protein
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sulphated glycosaminoglycans such as heparan sul-
phate proteoglycan (HSPG). Many of these proteins 
may act as molecular ‘chaperones’ enhancing Aβ 
ag gregation, ultimately forming a growing SP [7]. In 
addition, the molecular composition of NFT varies 
markedly depending on whether they are intracel-
lular NFT (I-NFT) or extracellular NFT (E-NFT). Unlike 
I-NFT, E-NFT are immunoreactive for glial fibrillary 
acidic protein (GFAP) and Aβ [144], and also contain 
significant amounts of amyloid-P [104] and ubiquitin 
[17]; these proteins likely to have been acquired after 
degeneration of NFT-containing neurons. 
These observations suggest that in early-onset 
FAD, Aβ within SP is the residue of the effects of 
a  pathogenic gene mutation which, via the accu-
mulation of toxic and insoluble Aβ oligomers, leads 
to the formation of NFT, cell death, and dementia. 
Since the pathological phenotype of FAD is similar, 
apart from age of onset, to that of the more common 
SAD [13,59,97], similar mechanisms, via additional 
genetic risk factors and/or environmental factors, 
are assumed to be involved in the pathogenesis of 
all types of AD [128]. A more fully developed version 
of the ACH incorporating these various features is 
shown in Figure 2. 
Problems and limitations of the amyloid 
cascade hypothesis
Formation, structure and function  
of amyloid precursor protein
There are a number of questions regarding APP 
and Aβ which have implications for the ACH. First, 
little is known of the normal functioning of APP [37], 
which remains a ‘current enigma’ [93]. Amyloid pre-
cursor protein has been implicated in various brain 
functions including development, learning, memory, 
and synaptic plasticity, and it may also be secreted 
as a  neuroprotectant [62,93]. Second, the detailed 
structure of APP does not appear to explain how 
aggregated peptides such as Aβ are formed [73]. One 
possibility is that excess APP overwhelms the normal 
degradation pathway leading to the formation of Aβ, 
as in DS. Third, some mutations of APP, e.g., amino 
acid changes at codon 717, appear to shed little light 
on its mechanism of action in AD [91]. Hence, amino 
acid substitutions at codon 717 in APP717 cases are 
not incorporated into amyloid deposits and hence, 
mutant Aβ may have additional metabolic effects 
which determine pathogenesis [79]. Fourth, secre-
tion of Aβ requires cleavage at both the N and C-ter-
Aβ – β-amyloid, Apo E – apolipoprotein E, APP – amyloid precursor protein, GFAP – glial fibrillary acidic protein, PSEN1/2 – presenilin genes 1 and 2, 
NFT – neurofibrillary tangles, pTau – hyperphosphorylated tau, SP – senile plaques 
Fig. 2. The amyloid cascade hypothesis (ACH) in a more fully developed form. 
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minal sites [83] and therefore, membrane damage 
may be necessary before Aβ can be formed [140], i.e., 
neuronal degeneration may precede Aβ formation. 
Fifth, Aβ toxicity requires micromolar concentrations 
of Aβ whereas levels in brain are frequently in the 
picomolar range [84]. Hence, AD may be caused by 
inflammatory reactions associated with activated 
microglia rather than by Aβ directly [84]. Moreover, 
in toxicity experiments, Aβ may not induce neuronal 
loss directly but may act to increase the risk of death 
of neurons from other causes [17,76,142].
Correlation of classical pathology  
with clinical dementia 
If the ACH is an accurate description of AD pathol-
ogy, then there should be a correlation between the 
abundance of SP and/or NFT and clinical dementia. 
However, the link between these lesions and cog-
nitive impairment is often complex both in humans 
[106] and in rodent models of AD [44]. Several 
studies have attempted to correlate the numerical 
density of SP and NFT in AD brain with patient age 
and duration or degree of dementia [19,117,140]. 
Hence, significant correlations have been reported 
between: (1) the quantity of Aβ in entorhinal cortex 
and degree of cognition [30], (2) density and sur-
face area of Aβ and months of severe dementia [19], 
(3) NFT counts and dementia in sectors CA1, CA4 and 
the subiculum [117], and (4) between neuritic SP and 
NFT and degree of dementia [140]. 
By contrast, Hyman et al. [65] found no quan-
titative measure of Aβ correlated with age in con-
trol patients, or with disease duration in AD, and 
suggested that Aβ did not accumulate in the brain 
throughout the course of the disease. That the rela-
tionship between SP and NFT and dementia is more 
complex was also emphasised by Bennett et al. [21]. 
No change in SP or NFT density was found from 
biopsy to autopsy suggesting that the pathology 
was well advanced before development of overt clin-
ical symptoms. In a further study of 97 elderly cases 
with no symptoms of dementia, AD-type pathology 
was observed in 20-40% of cases, and although NFT 
were age-related there was no correlation between 
Aβ load and age [106]. Similarly, a significant correla-
tion was observed between neuronal loss, NFT, and 
disease progression but not with Aβ [51]. In addi-
tion, some studies report that SP density declines 
with advancing AD, possibly as a result of the remov-
al of Aβ deposits by glial cells [10]. A  similar con-
clusion was reported by McKenzie et al. [85] who 
found that neither mean nor maximum SP density 
increased with age. Hence, SP may not progressively 
accumulate over the course of the disease but devel-
op over a limited period of time and then stabilise to 
a constant level or even decline. These results ques-
tion whether there is a direct or simple association 
between the formation and abundance of SP and 
NFT and developing dementia in AD as suggested 
by the ACH. 
Is the formation of Aβ and tau 
a reactive process?
In survivors of head injury, enhanced levels of 
APP are found in neuronal perikarya and in DN sur-
rounding Aβ deposits, similar pathological features 
to AD [45]. The processing of APP into Aβ in these 
cases occurs within the synaptic terminal fold of the 
axons, the presence of glial cells not being neces-
sary for the conversion. Hence, APP formation may 
be a  response to neuronal injury in AD [45]. Sub-
sequently, it was shown that specific neurons in 
medial temporal lobe secreted large quantities of 
APP and that there were more APP-immunoreactive 
neurons in these areas in head injury patients [85]. 
Hence, increased expression of APP in head trauma 
may be an acute-phase response to neuronal injury 
[112], overexpression of APP leading to Aβ deposi-
tion. This conclusion is supported by the localisation 
of several acute-phase proteins within the different 
morphological types of Aβ deposit including dif-
fuse, primitive, and classic deposits, e.g., amyloid-P, 
complement factors, and a-antichymotrypsin [7] 
(Table I). Furthermore, Regland and Gottfries [108] 
proposed that APP is involved in AD secondarily to 
maintain cell function. APP may therefore, maintain 
neuronal growth and survival and its putative neu-
rotrophic action is also suggested by the observation 
that it shares structural features with the precursor 
for epidermal growth factor [108]. Furthermore, NFT 
may be part of the neurons response to injury [109]. 
Animal experiments also suggest that the for-
mation of Aβ may be a  reaction to brain damage. 
Hence, experimental lesions that damage the nucle-
us basalis in rat brain elevate APP synthesis in the 
cerebral cortex suggesting APP production is a spe-
cific response to loss of functional innervation of the 
cortex [138]. Chemically induced lesions of the brain 
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produce similar results. For example, lesions of the 
nucleus basalis using N-methyl D-aspartate (NMDA) 
elevate APP synthesis in cortical polysomes [138] 
and, in areas of brain damaged by kainite [70], APP 
was recorded in dystrophic neurites adjacent to the 
lesion. In addition, intrathecal or intraparenchymal 
injections of a toxin induced the formation of APP in 
hippocampal neurons subsequent to neuronal dam-
age [68]. 
Lesion experiments can also induce pathological 
changes implicated in NFT formation. Hence, dener-
vation of the dopamine pathways and septal lesions 
affecting both the cholinergic system and g-amino-
butyric acid (GABA) neurons which project to the 
dentate gyrus, result in a loss of dendritic microtu-
bule associated protein 2 (MAP2) and the appear-
ance of tau-immunoreactive dentate gyrus granule 
cells [134]. Hence, denervation of these pathways 
may cause transsynaptic changes in dentate gyrus 
neurons and these changes could represent a pre-
cursor stage to NFT formation.
These observations suggest that Aβ and tau 
may be the consequence of neuronal degeneration 
and not its cause and therefore, do not initiate the 
pathological cascade in AD. Hence, Aβ and NFT for-
mation may occur ‘downstream’ of the ‘real’ caus-
ative events in AD but once formed, could initiate 
a secondary phase of degeneration.
Is the formation of neurofibrillary 
tangles related to Aβ?
Several attempts have been made to explain how 
Aβ may lead to NFT, as proposed by the ACH, but none 
have become universally accepted [23,47,100,101]. 
Alzheimer’s disease was first recognised as a  dis-
tinct disease entity in 1910 and was named after 
Alzheimer by Kraepelin based on the clinical and 
pathological description of the original cases [52]. 
Of the two original cases described by Alzheimer [2], 
however, both had numerous SP but only one of the 
cases had significant numbers of NFT [52], thus cre-
ating a controversy as to the relationship between 
the two ‘signature’ pathological features [58,72,87]. 
In addition, SP and NFT can develop alone in differ-
ent disorders, e.g., NFT in tangle-only dementia [143] 
and Aβ in hereditary cerebral haemorrhage with 
amyloidosis of the Dutch type (HCHA-D) [64]. These 
observations suggest a  more complex relationship 
between Aβ and tau formation than suggested by 
the ACH. 
Studies also suggest that SP and NFT exhibit 
distinct but independently distributed topographic 
patterns in the cerebral cortex in AD [12,64]. Braak 
and Braak [22] showed that tau pathology occurred 
first in entorhinal cortex, often in the absence of SP, 
whereas the subsequent spread and distribution of 
Aβ was more variable. Studies of the spatial patterns 
of SP and NFT also show them to be clustered, the 
clusters often being regularly distributed relative to 
the pia mater [3]. Clusters of SP and NFT, however, 
are not spatially correlated, which would not support 
a direct pathogenic link between them. Perez et al. 
[103], however, showed that Aβ25-35 could result in 
tau aggregation and that a decrease in Aβ aggrega-
tion was induced by tau peptides. Hence, aggregation 
of tau may be correlated with disassembly of Aβ 
which could explain the lack of spatial correlation 
[12]. In addition, SP and NFT may be temporally sep-
arated in the brain [82]. In entorhinal cortex [39] and 
in sector CA1 of the hippocampus [43], for example, 
NFT may precede the appearance of SP against the 
prediction of the ACH. In sector CA1, it is possible that 
Aβ is present in neurons before NFT are formed but 
not easily detectable by conventional methods [43].
Disconnection between the processes of Aβ and 
tau formation does not invalidate other features of 
the ACH. Hence, Aβ deposition may be the earliest 
lesion detectable in AD while tau formation occurs 
later by an independent process [66]. It is also pos-
sible that Aβ and tau formation are different conse-
quences of degeneration of the same neurons, SP 
forming on the axonal terminals of NFT-containing 
neurons [3,31,102], which could also explain the 
spatial separation of SP and NFT within the brain. 
Evidence from transgenic experiments
Based on the ACH, a variety of transgenic rodent 
models have been developed in an attempt to repli-
cate AD pathology, including those based on single, 
double, and triple-mutation. Single mutation models 
usually involve various APP transgenes only. Hence, 
in the APP:V642I mouse, there was an increase 
in Aβ42 deposition, but no mature SP or NFT were 
formed [71], this result being fairly typical of such 
experiments. In the ‘double Swedish model’ (APP: 
K670N, M671L), however, Aβ deposits similar to 
those found in AD were formed, the deposits being 
immunoreactive for Apo E, but no NFT were observed 
[120]. In the ‘Indian/Swedish mutation model’, both 
diffuse and compact-type Aβ deposits were observed 
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at 9-10 months of age, amyloid deposition increas-
ing with age, and neocortex and amygdala being 
affected first followed by hippocampus and thala-
mus [38]. In addition, using the APP:Tg2576 mouse, 
increased Aβ-induced oxidative stress was observed 
which encouraged increased activity of stress-relat-
ed kinases and subsequently, tau phosphorylation in 
neurites surrounding SP [107]. 
Double mutation models usually include muta-
tions of both APP and PS1 transgenes. In one study 
(APP: K670N, M671L; PS1: M146L), long-term potenti-
ation (LTP) of neurons was observed as early as three 
months, reduced LTP paralleling the appearance of 
SP [135]. In a similar model, which also incorporated 
an APP V717I mutation, there was age-related loss of 
pyramidal neurons in the hippocampus CA sectors 
including at sites devoid of Aβ deposition [119]. In 
a further APP/PS model, Aβ deposits were observed 
at eight weeks and hyperphosphorylated tau as 
punctate deposits at 24 weeks, consistent with the 
ACH, but DN were not as heavily labelled as those in 
AD [74].
A few transgenic experiments have involved triple 
mutation models (APP, PS1 and tau). In one exper-
iment (APP: Swedish mutation, PS1: M146V, tau: 
P301L), Aβ and tau pathology was present in tem-
poral lobe with regional specificity similar to AD, Aβ 
deposition occurring before tau formation as predict-
ed by the ACH [98]. In further experiments involving 
this model, AD immunotherapy was found to reduce 
Aβ and early tau epitopes also suggesting a  direct 
pathogenic relationship between the two patholo-
gies [99].
Hence, the presence of an APP mutation alone 
or in combination with PSEN1 can result in Aβ depo-
sition, but apart from evidence of hyperphosphory-
lated tau in neurites associated with SP, do not 
appear to induce NFT or a  significant inflammato-
ry response. The presence of tau transgenes in the 
form of a  triple model appears to be necessary to 
more fully replicate AD pathology consistent with 
independent formation of Aβ and tau. However, in 
an APP-transgenic model, a  reduction in endoge-
nous tau ameliorated some of the effects mediated 
by Aβ which suggests a link between the two patho-
logies [110,111].
In conclusion, it is difficult to decide whether the 
presence of a specific mutation directly causes cell 
death as a  result of Aβ-mediated toxicity or deter-
mines whether Aβ is secreted by neurons already 
damaged by a different process or from aging. A fur-
ther problem is formation of Aβ may initiate a sec-
ondary phase of neurodegeneration that is difficult 
to distinguish from primary neuronal damage due 
to other causes. Nevertheless, a  recent model, viz., 
TgF344-AD which incorporates mutant APP and 
PS1 genes, exhibited age-dependent amyloidosis, 
tauo pathy, gliosis, apoptotic loss of neurons in cor-
tex and hippocampus, in addition to cognitive dis-
turbance, and may offer a more complete model of 
AD [29].
Therapies for Alzheimer's disease based 
on the amyloid cascade hypothesis
There are many potential targets for AD thera-
py including APP cleavage, cytoskeletal destruction, 
neurotubule and ion homeostasis, metal ion accu-
mulation, protein misfolding, oxidative stress, neuro-
nal death, and gene mutation [24]. Therapies based 
on the ACH, however, have received considerable 
attention. Possible treatment strategies based on 
the ACH include inhibition of APP, inhibition of the 
proteases that liberate Aβ, and retarding maturation 
of Aβ into SP [121]. 
Some therapies have been based on targeting 
βACE1 [41]. In mice lacking this gene, there was 
a little apparent effect on behaviour and promising 
results were obtained in reducing the levels of SP. 
In humans, however, βACE1 also cleaves substrates 
involved in myelination, retinal homoeostasis, brain 
circuitry, and synaptic function, all of which could be 
affected if the enzyme was targeted [41]. In addi-
tion, treatment with g-secretase inhibitors has been 
tested in rodent models and in humans. In rodents, 
early treatment with g-secretase inhibitor can pre-
vent or ameliorate Aβ deposition but established SP 
[1] and hyperphosphorylated tau aggregates [99] 
appear more resistant. In this regard, the failure of 
semagacestat in clinical trials, a  well-characterised 
g-secretase inhibitor, was particularly notable as Aβ 
deposition was reduced by this compound in both 
transgenic mice and humans [95].
There have also been clinical trials designed to 
remove or prevent Aβ formation using specific anti-
bodies. Such antibodies can capture peripheral Aβ 
and prevent its re-entry from the periphery to the 
brain [32,33]. In addition, binding of specific antibod-
ies to Aβ in deposited SP could activate microglia, 
thereby potentially clearing plaques by phagocytosis 
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[118]. Hence, a vaccine against Aβ was developed by 
activating microglia to remove SP [92]. Neverthe-
less, in clinical trials, some patients exhibited brain 
inflammation as a  result of lymphocyte infiltration 
and elevated protein levels suggesting a breakdown 
of the blood brain barrier and entry of T-cells into 
the brain. Hence, Aβ-specific activated T-helper cells 
may amplify existing pro-inflammatory conditions 
present in AD. In addition, cytotoxic T-cells could 
at tack APP present on the surface of many cells in-
cluding neurons and release Aβ. 
Treatment with bapineuzumab resulted in an 
over all Aβ deposit load and degree of CAA similar to 
controls [113]. Treatment, however, also altered the 
Aβ peptide profile of the patient, decreasing the pro-
portion of Aβ42 and increasing that of Aβ40, but none 
of the treated patients exhibited improved cognition 
[113]. Subsequently, there has been a cessation of 
phase III clinical trials involving bapineuzumab in 
patients with mild to moderate levels of disease 
[26]. No treatment benefits have been established 
and several side effects reported. One possible 
ex planation is that Aβ oligomers are pro-oxidants 
which combine with redox-active metals to form 
reactive species [130]. Hence, reducing Aβ may fail 
to halt cognitive decline because it is the effect of 
oxidative stress rather than Aβ directly which results 
in AD, Aβ and tau being upregulated to address the 
redox imbalance, possibly further accelerating the 
disease process [130].
As a  result, after nearly 25 years of the theory, 
no new therapeutic agents for AD have reached the 
clinic based on the ACH [93]. Recent remarks by Cas-
tellani and Perry [26] that studies of Aβ metabolism 
have essentially been ‘exhausted to no avail’ rein-
force this conclusion. Nevertheless, there are two 
questions raised by these trials. First, by how much 
should Aβ be reduced in brain to obtain a therapeu-
tic effect [69]? Estimates of the total amount of Aβ 
deposited in an AD brain vary from approx. 4 mg 
[94] to 10 mg per brain [53]. In addition, it is dif-
ficult to quantify the rate of production of new Aβ 
in humans, which is often extrapolated from rodent 
cell culture models [18], thus making it difficult to 
establish treatment dosage. Second, are treatments 
applied to patients ‘too late’ in the disease process, 
i.e., after significant neuronal degeneration has 
already occurred, for trials to be effective? Recent 
criteria for the identification of pre-symptomatic AD 
using biomarkers and brain scan [89] may enable 
treatments to be tested at a much earlier stage of 
the disease and therefore, a more rigorous trial of 
the various treatments based on the ACH are possi-
ble in future.
Aβ – β-amyloid, Apo E – apolipoprotein E, APP – amyloid precursor protein, PSEN1/2 – presenilin genes 1 and 2, NFT – neurofibrillary tangles,  
SP – senile plaques 
Fig. 3. A modified scheme based on the amyloid cascade hypothesis (ACH). 
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A modified scheme for Alzheimer's 
disease pathogenesis 
These observations taken together suggest that 
the ACH may not provide a  complete explanation 
of AD pathogenesis. There is doubt regarding the 
primary role of Aβ, whether Aβ leads to tau forma-
tion, and whether SP and NFT are directly related 
to clinical dementia. There are two possible direc-
tions of future research. First, to attempt a  further 
understanding of the mechanisms of Aβ-mediated 
neuronal loss within the context of the ACH [69] or 
second, to modify the ACH itself.
This review advocates the second approach and 
proposes a  modified scheme based on the ACH, 
which incorporates the various concerns and ques-
tions raised (Fig. 3). First, the primary factor in this 
scheme is age-dependent breakdown of anatomical 
systems and pathways within the brain and conse-
quent loss of synapses [25]. The extent of this aging 
effect, which begins early in life, is mediated by 
the degree of lifetime stress (the ‘allostatic load’). 
The brain is the ultimate mediator of stress-relat-
ed mortality through hormonal changes resulting 
in hypertension, glucose intolerance, cardiovascu-
lar disease, and immunological problems [25]. Sec-
ond, the consequence of increasing allostatic load 
is gradual synaptic disconnection, neuronal degen-
eration, and the upregulation of genes determining 
various reactive and breakdown products resulting 
in the formation of Aβ and tau [14,96,108,138]. Third, 
in small numbers of families, specific APP or PSEN 
mutations influence the outcome of this age-related 
degeneration by determining the quantity, solubility, 
and/or toxicity of the molecular product. Cells have 
mechanisms to protect against the accumulation 
of misfolded and aggregated proteins including the 
ubiquitin system and the phagosome-lysosome sys-
tem. Neuronal degeneration in individuals with spe-
cific mutations results in the accelerated formation of 
Aβ and tau, and then a further phase of ‘secondary’ 
neurodegeneration, which overwhelms the protec-
tion systems. Early-onset FAD is the consequence of 
this process. Fourth, in individuals without a specific 
genetic mutation, and where more complex genetic 
and environmental risk factors are present, the out-
come of age-related loss of synapses is mainly solu-
ble and smaller quantities of insoluble proteins which 
are degraded by the cellular protection systems and 
do not significantly accumulate to form SP and NFT. 
With advancing age, however, the protective systems 
become less effective resulting in slowly accumulat-
ing quantities of Aβ and tau. The result of these insid-
ious processes is that the cellular protection systems 
do not become overwhelmed until much later in life, 
the consequence being late-onset SAD. 
This modified scheme may explain the similari-
ties in the phenotypes of FAD and SAD, why SP and 
NFT often appear to be distributed independently, 
and reflects data suggesting that Aβ and tau may be 
formed as a response to cellular degeneration.
Predictions of the modified hypothesis
The modified hypothesis makes a number of pre-
dictions that could be usefully investigated to test 
its validity. First, significant signs of neuronal degen-
eration should precede Aβ deposition especially in 
late-onset SAD. Second, any toxic effects of Aβ will 
be secondary rather than primary. Third, SP and NFT 
are both the consequences of neuronal degenera-
tion essentially arising independently as a  result of 
age-specific synapse loss. Fourth, in transgenic exper-
iments, the effect of the transgene will be age-depen-
dent. Hence, in a model which incorporates an APP: 
V717I mutation, for example, there was an age-relat-
ed loss of pyramidal neurons in the hippocampus CA 
sectors including at sites devoid of plaque deposition 
[119], consistent with this prediction. 
Implications of the modified hypothesis
The modified scheme has a  number of implica-
tions. First, that SAD is not a disease linked primarily 
to defective genes but a  complex syndrome depen-
dant on the rate of aging and indirectly influenced 
by numerous genetic and environmental risk factors 
acting over a  lifetime. Second, the hypothesis ques-
tions whether the presence, distribution, and molec-
ular determinants of SP and/or NFT should continue 
to play a primary role in the pathological diagnosis of 
AD. If SP and NFT are ultimately the products of brain 
degeneration and not its initial cause [14], they may 
represent relatively late stages of the disease. Hence, 
there could be cases of AD that are difficult to classi-
fy pathologically because they may have insufficient 
numbers of SP and NFT or exhibit early developmen-
tal stages of these pathologies. In addition, if SP and 
NFT represent the consequence of neurodegeneration 
affecting different parts of neurons rather than being 
characteristic of a particular disease, there are likely to 
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be many cases that show combinations of pathologi-
cal features, i.e., there will be some overlap between 
different disorders. Numerous examples of such cas-
es have been reported in the literature, e.g., dementia 
with Lewy bodies (DLB) with associated AD pathology, 
Creutzfeldt-Jakob disease (CJD) with AD, Pick’s disease 
(PkD) with AD, and these cases are often difficult to 
classify within the existing system [15]. Finally, should 
significant efforts continue to be devoted to immu-
notherapy and other treatments designed to remove 
Aβ from the brain? Such treatments could be benefi-
cial in limiting the degree of secondary degeneration 
caused by Aβ. Nevertheless, Aβ might also be benefi-
cial to the nervous system by promoting neurogenesis 
[80] and having a range of other protective functions 
[77]. In addition, excessive removal of Aβ could poten-
tially reduce chelation within the brain resulting in 
enhanced oxidative stress [16].
Conclusions
Since 1992, the ACH has played the most influen-
tial role in explaining the pathogenesis of AD. It pro-
poses that the deposition of Aβ is the initial patho-
logical event leading to the formation of SP and NFT, 
death of neurons, and ultimately dementia. A num-
ber of major limitations of the ACH have been iden-
tified: (1) SP and NFT may develop independently, 
(2) SP and NFT may be the products rather than the 
cause of neurodegeneration in AD, (3) SP and NFT 
may not be closely correlated with the onset, sever-
ity and development of clinical dementia, (4) trans-
genic rodent models do not generally replicate all 
aspects of AD pathology, and (5) treatments based 
on the ACH have not been successful. A modification 
to the ACH is proposed which may better explain the 
pathogenesis of AD, especially in late-onset cases of 
the disease. The modified scheme makes a number 
of predictions which could be usefully investigated.
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